trending Market Intelligence /marketintelligence/en/news-insights/trending/E9MVa6ztndMWdOIP58bkYA2 content esgSubNav
In This List

Mirati Therapeutics starts $75M underwritten public offering

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Mirati Therapeutics starts $75M underwritten public offering

Mirati Therapeutics Inc. started a $75 million underwritten public offering of its common shares.

The San Diego-based biotechnology company will give underwriters an option to buy up to an additional $11.3 million in shares.

J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Cowen and Co. LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC are offering's joint book-running managers.

Mirati Therapeutics develops drugs that target genetic changes in cancer cells which cause tumors to grow and spread.